Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting

被引:0
|
作者
Pfister, Isabel B. [1 ,2 ]
Schild, Christin [1 ,2 ]
Garweg, Justus G. [1 ,2 ,3 ]
机构
[1] Berner Augenklin, Swiss Eye Inst, Bern, Switzerland
[2] Berner Augenklin, Clin Vitreoretinal Dis, Bern, Switzerland
[3] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland
来源
PLOS ONE | 2024年 / 19卷 / 11期
关键词
MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB; ATROPHY; VISION; BEVACIZUMAB; THERAPY; DELAY;
D O I
10.1371/journal.pone.0314167
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose To test to what degree retinal fluid (RF) after the loading phase and at the end of year 1 predicts long-term functional outcomes in neovascular macular degeneration (nAMD), as do macular (MA) atrophy, treatment density and treatment interval extension.Methods In this retrospective single-center cohort study, a consecutive series of eyes with treatment-na & iuml;ve nAMD followed under a treat-and-extend (T&E) protocol followed over >= 2 years. Best-corrected visual acuity (BCVA), presence of retinal fluid (RF) and macular atrophy (MA) were registered along with central retinal thickness (CRT) and treatment density over time. The relationship between these variables was tested by regression analysis.Results A total of 433 eyes were followed for 4.9 +/- 2.2 years. A series of univariate analyses were run to select the covariates for the final multivariate regression model. CRT after loading, time to dryness, intraretinal fluid and MA after one year were found to predict visual function over 2 to 5 years. A final regression model was adjusted for visual acuity (VA) at baseline and showed that CRT after loading was predictive only in the short term (2 years) and that MA had the greatest predictive value for VA after 2 to 5 years. Intraretinal fluid (IRF) significantly predicted VA only after 4 years. The final regression model explained 21 to 32% of the variation in VA.Conclusions In this large retrospective cohort, the presence of MA after one year was the strongest predictor of VA after 2 to 5 years, explaining a vision loss of 13 to 20 letters. The presence of IRF and SRF at any point of time had a comparably weak predictive potential for the outcomes over 5 and more years.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Long-term outcomes of anti-VEGF treatment for diabetic macular edema in a real-world clinical setting
    Maggio, Emilia
    Polito, Antonio
    Sartore, Mauro
    Pertile, Grazia
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [2] Real-World Treatment Patterns in a Population With Neovascular AMD Treated With Anti-VEGF Agents
    Urbano, Catherine A.
    Maatouk, Christopher
    Greenlee, Tyler
    Chen, Andrew
    Conti, Thais F.
    Briskin, Isaac
    Singh, Rishi P.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2021, 52 (04): : 190 - 198
  • [3] Long-Term Impact of Diabetic Retinopathy on Response to Anti-VEGF Treatment in Neovascular AMD
    Boscia, Giacomo
    Bacherini, Daniela
    Vujosevic, Stela
    Grassi, Maria Oliva
    Borrelli, Enrico
    Giancipoli, Ermete
    Landini, Luca
    Pignataro, Mariagrazia
    Alessio, Giovanni
    Boscia, Francesco
    Viggiano, Pasquale
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (10)
  • [4] Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
    Jan Niklas Lüke
    Hamdi Alquoqa
    Ahmad Alsamman
    Bayan Aljabary
    F. Schaub
    L. M. Heindl
    International Ophthalmology, 2023, 43 : 13 - 25
  • [5] Baseline predictors for good long-term visual outcomes in the treatment of neovascular AMD with intravitreal anti-VEGF therapy.
    Jung, Jesse J.
    Chen, Christine Y.
    Mrejen, Sarah
    Gallego-Pinazo, Roberto
    Xu, Luna
    Marsiglia, Marcela
    Boddu, Sucharita
    Freund, K. Bailey
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [6] Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
    Lueke, Jan Niklas
    Alquoqa, Hamdi
    Alsamman, Ahmad
    Aljabary, Bayan
    Schaub, F.
    Heindl, L. M.
    INTERNATIONAL OPHTHALMOLOGY, 2023, 43 (01) : 13 - 25
  • [7] Treatment intervals with anti-VEGF drugs: Evaluating the unmet need in a real-world neovascular AMD national database
    Zarranz-Ventura, Javier
    Garay-Aramburu, Gonzaga
    Calvo, Pilar
    Garcia-Arumi, Jose
    Arruabarrena, Carolina
    Arnaiz, Pablo
    Garcia-Lunar, Paula
    Sararols-Ramsay, Laura
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [8] Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD
    Freund, K. Bailey
    Engelbert, Michael
    Fine, Howard F.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (05): : 508 - 512
  • [9] LONG-TERM VISUAL OUTCOMES FOLLOWING ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION; REAL-WORLD EVIDENCE FROM A UK DISTRICT HOSPITAL
    Mansoor-Ali, Nyaish
    Thakur, Shakti
    EYE, 2024, 38 : 169 - 169
  • [10] Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting
    Calugaru, Dan
    Calugaru, Mihai
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2018, 196 : 208 - 209